Delafloxacin (Baxdela™) is a fluoroquinolone antibacterial with activity against 
both gram-positive and gram-negative pathogens being developed by Melinta 
Therapeutics. The drug is being investigated or considered as a treatment for 
various bacterial infections and in June 2017 received approval in the USA for 
the treatment of acute bacterial skin and skin structure infections. This 
article summarizes the milestones in the development of delafloxacin leading to 
this first global approval for the treatment of acute bacterial skin and skin 
structure infections.